ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer
Rowan Miller, Alexandra Léary, Clare L. Scott, Violeta Serra, Christopher J. Lord, David D.L. Bowtell, David K. Chang, Dale W. Garsed, Jos Jonkers, Jonathan A. Ledermann, Serena Nik‐Zainal, Isabelle Ray‐Coquard, Sohrab P. Shah, Xavier Matías‐Guiu, Elizabeth M. Swisher, Lucy Yates
Topics & Concepts
MedicinePARP inhibitorHomologous recombinationOvarian cancerBiomarkerOncologyHomologous chromosomePoly ADP ribose polymeraseInternal medicineCancerGeneticsDNAGeneBiologyPolymerasePARP inhibition in cancer therapyDNA Repair MechanismsOvarian cancer diagnosis and treatment